Skip to main content
SpringerLink
Log in

Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders

  • Published:
Human Physiology Aims and scope Submit manuscript

Abstract

Introduction. Hemorheological abnormalities in patients with Ph-negative myeloproliferative disorders (MPD) may lead to the development and/or progression of cerebrovascular pathology. Adequate preventive therapy in such cases lowers the risk of cerebral thrombotic complications. Objective. Evaluation of the effect of dipyridamole and acetylsalicylic acid (ASA) on platelet and erythrocyte aggregation, as well as on morphofunctional properties of erythrocytes in patients with cerebrovascular disease (CVD) due to MPD. Materials and methods. The study comprised 40 patients with various forms of CVD and Рh-negative MPD: 20 patients received dipyridamole, and 20 received ASA for prevention of cerebral thrombotic complications. Mean patient’s age was 44.6 years [35; 58.5]. A thorough clinical and neurological examination was performed, as well as neuroimaging studies, coagulation tests, analysis of platelet aggregation and rheological properties of erythrocytes. Results. Within the observation period (median—6.3 months) no acute cerebrovascular events in both groups were registered. Platelet aggregation (induced by ADP or adrenaline) was similar in both groups. Dipyridamole and ASA were also similar in their effect on functional properties of erythrocytes. Conclusion. Our findings suggest that the therapeutic effect of dipyridamole concerning CVD is similar to that of ASA. Dipyridamole can be recommended for use in patients with Рh-negative MPD if other antiplatelet agents are contraindicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

REFERENCES

  1. Duangnapasatit, B., Rattarittamrong, E., Rattanathammethee, T., et al., Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms, Asian Pac. J. Cancer Prev., 2015, vol. 16, no. 12, pp. 5013–5018. PMID 26163633. doi 10.7314/APJCP.2015.16.12.5013

    Article  PubMed  Google Scholar 

  2. Tefferi, A., Thiele, J., and Vardiman, J.W., The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos, Cancer, 2009, vol. 115, no. 9, pp. 3842–3847. PMID 19472396. doi 10.1002/cncr.24440

    Article  CAS  PubMed  Google Scholar 

  3. Tefferi, A., Pathogenesis of myelofibrosis with myeloid metaplasia, J. Clin. Oncol., 2005, vol. 23, no. 33, pp. 8520–8530. PMID 16293880. doi 10.1200/JCO. 2004.00.9316

    Article  CAS  PubMed  Google Scholar 

  4. Alvarez-Larrán, A., Cervantes, F., Bellosillo, B., et al., Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients, Leukemia, 2007, vol. 21, no. 6, pp. 1218–1223. PMID 17519959. doi 10.1038/sj.leu.2404693

    Article  PubMed  Google Scholar 

  5. Kaifie, A., Kirschner, M., Wolf, D., et al., Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J. Hematol. Oncol., 2016, vol. 9, p. 18. doi 10.1186/ s13045-016-0242-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Arellano-Rodrigo, E., Alvarez-Larrán, A., Rever-ter, J.C., et al., Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status, Haematologica, 2006, vol. 91, no. 2, pp. 169–175. PMID 16461300

    CAS  PubMed  Google Scholar 

  7. Falanga, A., Marchetti, M., Vignoli, A., et al., V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules, Exp. Hematol., 2007, vol. 35, no. 5, pp. 702–711. PMID 17577920

    Article  CAS  PubMed  Google Scholar 

  8. Falanga, A., Marchetti, M., Barbui, T., and Smith, C.W., Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils, Semin. Hematol., 2005, vol. 42, no. 4, pp. 239–247. doi 10.1053/j.seminhematol.2005.05.023

    Article  CAS  PubMed  Google Scholar 

  9. Marchetti, M. and Falanga, A., Leukocytosis, JAK2V617F mutation, and homeostasis in myeloproliferative disorders, Pathophysiol. Haemostasis Thromb., 2008, vol. 36, nos. 3–4, pp. 148–159. PMID 19176988. doi 10.1159/000175153

    Article  CAS  Google Scholar 

  10. Falanga, A., Marchetti, M., Vignoli, A., et al., Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera, Exp. Hematol., 2005, vol. 33, no. 5, pp. 523–530. PMID 15850829. doi 10.1016/j.exphem.2005.01.015

    Article  CAS  PubMed  Google Scholar 

  11. De Stefano, V., Za, T., Rossi, E., et al., Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia, Haematologica, 2009, vol. 94, no. 5, pp. 733–737. PMID 19336736. doi 10.3324/haematol.13869

    Article  PubMed  PubMed Central  Google Scholar 

  12. Campbell, P.J., MacLean, C., Beer, P.A., et al., Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort, Blood, 2012, vol. 120, no. 7, pp. 1409–1411. doi 10.1182/ blood-2012-04-424911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Derry, S. and Loke, Y.K., Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis, Br. Med. J., 2000, vol. 321, no. 7270, pp. 1183–1187. https://doi.org/10.1136/bmj.321.7270.1183.

    Article  CAS  Google Scholar 

  14. Tanashyan, M., Kuznetsova, P., Shabalina, A., et al., Clinical characteristics of cerebrovascular pathology with patients suffering from Ph-negative myeloproliferative disease, Cerebrovasc. Dis. Extra, 2016, vol. 6, no. 3, pp. 66–70. PMID 27598581. doi 10.1159/000448597

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kim, H.H. and Liao, J.K., Translational therapeutics of dipyridamole, Arterioscler., Thromb., Vasc. Biol., 2008, vol. 28, pp. 39–42. PMID 18174451. doi 10.1161/ATVBAHA.107.160226

    Article  CAS  Google Scholar 

  16. Leonardi-Bee, J., Bath, P.M., Bousser, M.G., et al., Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials, Stroke, 2005, vol. 36, no. 1, pp. 162–168. doi 10.1161/01.STR.0000149621.95215.ea

    Article  CAS  PubMed  Google Scholar 

  17. Tanashyan, M.M. and Domashenko, M.A., Dipiridamol in the complex therapy of chronic cerebrovascular disease, Nervnye Bolezni, 2012, no. 3, pp. 27–30.

  18. Michiels, J.J., Koudstaal, P.J., and Mulder, A.H., Transient neurologic and ocular manifestations in primary thrombocythemia, Neurology, 1993, vol. 43, pp. 1107–1110. PMID 8170552

    Article  CAS  PubMed  Google Scholar 

  19. Lengfelder, E., Hochhaus, A., Kronawitter, U., et al., Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages, Br. J. Haematol., 1998, vol. 100, pp. 15–23. PMID 9450785

    Article  CAS  PubMed  Google Scholar 

  20. Michiels, J.J., Berneman, Z., and Schroyens, W., Plateled-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia, Platelets, 2006, vol. 17, pp. 528–544. PMID 17127481. doi 10.1080/09537100600758677

    Article  CAS  PubMed  Google Scholar 

  21. Harrison, C., Pregnancy and its management in the Philadelphia negative myeloproliferative diseases, Br. J. Haematol., 2005, vol. 129, pp. 293–306. PMID 15842653. doi 10.1111/j.1365-2141.2005.05400.x

    Article  CAS  PubMed  Google Scholar 

  22. Tanashyan, M.M., Kuznetsova, P.I., Lagoda, O.V., et al., Myeloproliferative diseases and ischemic stroke, Ann. Klin. Eksp. Nevrol., 2014, vol. 8, no. 2, pp. 41–45.

    Google Scholar 

  23. Tanashyan, M.M. and Domashenko, M.A., Kurantil use for patients with chronic cerebrovascular disease, Nervnye Bolezni, 2005, no. 3, pp. 8–11.

Download references

Author information

Authors and Affiliations

  1. Research Center of Neurology, Moscow, Russia

    M. M. Tanashyan, P. I. Kuznetsova, A. A. Shabalina & A. A. Raskurazhev

Authors
  1. M. M. Tanashyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. I. Kuznetsova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Shabalina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. Raskurazhev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Raskurazhev.

Additional information

The article is published in the original.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanashyan, M.M., Kuznetsova, P.I., Shabalina, A.A. et al. Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders. Hum Physiol 44, 896–900 (2018). https://doi.org/10.1134/S0362119718080133

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0362119718080133

Keywords:

Search

Navigation